Cited by 165Blood Pressure and Hypertension StudiesCardiovascular Health and Disease PreventionHormonal Regulation and Hypertension

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk

Gupta, Ajay K., Nasothimiou, Efthimia G., Chang, Choon L., Sever, Peter S., Dahlöf, Bjorn, Poulter, Neil R.·2011·Journal of Hypertension

DOI 10.1097/hjh.0b013e32834a8a42

Open this paper in CoChat — free account

Abstract

BACKGROUND: Resistant hypertension is a well recognized clinical entity, which has been inadequately researched to date. METHODS: A multivariable Cox model was developed to identify baseline predictors of developing resistant hypertension among 3666 previously untreated Anglo-Scandinavian Cardiac Outcome Trial (ASCOT) patients and construct a risk score to identify those at high risk. Secondary analyses included evaluations among all 19 257 randomized patients. RESULTS: One-third (1258) of previously untreated, and one-half (9333) of all randomized patients (incidence rates 75.2 and 129.7 per 1000 person-years, respectively) developed resistant hypertension during a median follow-up of 5.3 and 4.8 years, respectively. Increasing strata of baseline SBP (151-160, 161-170, 171-180, and >180 mmHg) were associated with increased risk of developing resistant hypertension [hazard ratio 1.24 (95% confidence interval, CI 0.81-1.88), 1.50 (1.03-2.20), 2.15 (1.47-3.16), and 4.43 (3.04-6.45), respectively]. Diabetes, left ventricular hypertrophy, male sex, and raised BMI, fasting glucose, and alcohol intake were other significant determinants of resistant hypertension. Randomization to amlodipine ± perindopril vs. atenolol ± thiazide [0.57 (0.50-0.60)], previous use of aspirin [0.78 (0.62-0.98)], and randomization to atorvastatin vs. placebo [0.87 (0.76-1.00)] significantly reduced the risk of resistant hypertension. Secondary analysis results were similar. The risk score developed allows accurate risk allocation (Harrell's C-statistic 0.71), with excellent calibration (Hosmer-Lemeshow χ statistics, P = 0.99). A 12-fold (8.4-17.4) increased risk among those in the highest vs. lowest risk deciles was apparent. CONCLUSION: Baseline SBP and choice of subsequent antihypertensive therapy were the two most important determinants of resistant hypertension in the ASCOT population. Individuals at high risk of developing resistant hypertension can be easily identified using an integer-based risk score.

Integrity signals

Registry

Crossref · 10.1097/hjh.0b013e32834a8a42

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
2013 ESH/ESC Guidelines for the management of arterial hypertension
Authors Task Force Members, Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cífková, R., Backer, G. D., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,739
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies
(2002) · The Lancet · doi:10.1016/s0140-6736(02)11911-8 · Cited by 10,266
2007 Guidelines for the Management of Arterial Hypertension
Mancia, G., Backer, G. D., Dominiczak, A. F., Cífková, R., Fagard, R. H., Germanò, G., Grassi, G. M., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,870
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
Dahlöf, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67185-1 · Cited by 2,909
Self-citation
Resistant Hypertension: Diagnosis, Evaluation, and Treatment
Calhoun, D. A., Jones, D. W., Textor, S. C., Goff, D. C., Murphy, T. P., Toto, R. D., White, A. J., Cushman, W. C., White, W. B., Sica, D. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.189141 · Cited by 2,240
Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension
Rothwell, P. M., Howard, S. C., Dolan, E., O'Brien, E., Dobson, J. E., Dahlöf, B., Sever, P. S., & Poulter, N. R. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60308-x · Cited by 1,784
Self-citation
Differential Impact of Blood Pressure–Lowering Drugs on Central Aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFE) Study
The CAFE Investigators, CAFE Steering Committee and Writing Committee, Williams, B., Lacy, P. S., Thom, S. M., Cruickshank, K., Stanton, A., Collier, D., Hughes, A. D., Thurston, H., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.595496 · Cited by 1,645
A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease
Pepine, C. J., Handberg, E. M., Cooper‐DeHoff, R. M., Marks, R. G., Kowey, P. R., Messerli, F. H., Mancia, G., Cangiano, J. L., García-Barreto, D., Keltai, M., et al. (2003) · JAMA · doi:10.1001/jama.290.21.2805 · Cited by 1,278
Applying Cox Regression to Competing Risks
Lunn, M., & McNeil, D. (1995) · Biometrics · doi:10.2307/2532940 · Cited by 1,017

Flagged first, then by citations

Show all 26 references

Sorted by citations

Items 101–165 of 165

Management of resistant hypertension
Hasan, M. A., Stewart, M. H., Lavie, C. J., & Ventura, H. O. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000635 · Cited by 4
Characterizing apparent treatment resistant hypertension in the United States: insights from the All of Us Research Program
Alshahawey, M., Jafari, E. A., Smith, S. M., & McDonough, C. W. (2024) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocae227 · Cited by 6
Uncontrolled arterial hypertension: main causes, features of pathogenesis and approaches to treatment
Denisova, A. R., Solntseva, T. D., Анатольевна, С. О., & Chazova, I. E. (2021) · Systemic Hypertension · doi:10.26442/2075082x.2021.1.200724 · Cited by 5
Apparent treatment-resistant hypertension among elderly Korean hypertensives: an insight from the HIT registry
Choi, S., Kim, M. K., Han, S., Han, S. H., Lee, B. K., Lee, S. U., Hur, S.-J., Lim, S. W., Moon, K., Lee, S.-Y., et al. (2013) · Journal of Human Hypertension · doi:10.1038/jhh.2013.76 · Cited by 4
Identifying Patients With Resistant Hypertension and Options for Clinical Management
Cheung, T. T., & Cheung, B. M. Y. (2012) · Future Cardiology · doi:10.2217/fca.12.66 · Cited by 4
Impact of Implementing the 2013 ACC/AHA Cholesterol Guidelines on Vascular Events in a Statewide Community‐Based Practice Registry
Egan, B. M., Li, J., Fleming, D. O., White, K., Connell, K., Davis, R. A., & Sinopoli, A. (2015) · Journal of Clinical Hypertension · doi:10.1111/jch.12727 · Cited by 4
Renal denervation for resistant hypertension: acute results and long-term follow-up.
Korovesis, S., Giazitzoglou, E., Pantos, I., Tzanalaridou, E., Kokladi, M., Venetsanakos, I., Paxinos, G., & Katritsis, D. G. (2014) · PubMed · Cited by 3
Preferred Fourth-Line Pharmacotherapy for Resistant Hypertension: Are We There Yet?
Prosser, H. C. G., Gregory, C., Hering, D., Hillis, G. S., Perry, G. J., Rosman, J. B., Schultz, C. J., Thomas, M., Watts, G. F., & Schlaich, M. P. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0728-z · Cited by 3
Prognostic value of risk factors for cardiovascular diseases and target organ damages for the occurrence of resistant hypertension
Lazutkina, A. Y., & Горбунов, В. В. (2015) · Terapevticheskii arkhiv · doi:10.17116/terarkh201587419-23 · Cited by 3
Current Status of Renal Denervation in Hypertension
Briasoulis, Α., & Bakris, G. L. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0781-2 · Cited by 3
Chronic kidney disease and cardiovascular events: a focus on central blood pressure
Murkamilov, I. T., Айтбаев, К. А., Sabirov, I. S., Fomin, V. V., & Yusupov, F. A. (2017) · Systemic Hypertension · doi:10.26442/sg29181 · Cited by 3
Diagnosis and Evaluation
Fuchs, F. D. (2017) · Springer eBooks · doi:10.1007/978-3-319-63272-8_3 · Cited by 3
Predicting the risk of apparent treatment-resistant hypertension: a longitudinal, cohort study in an urban hypertension referral clinic
Buhnerkempe, M., Botchway, A., Morales, C. E. N., Prakash, V., Hedquist, L., & Flack, J. M. (2018) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2018.09.006 · Cited by 3
Resistant Hypertension: Questions and Contemporary Answers
Podzolkov, V. I., Bragina, A. E., & Osadchiy, K. K. (2019) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2019-15-4-568-577 · Cited by 3
Resistant Hypertension
Boolani, H., Sinha, A., & Randall, O. S. (2013) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-013-0326-9 · Cited by 3
Predictive Factors of Apparent Treatment Resistant Hypertension Among Patients With Hypertension Identified Using Electronic Health Records
Lin, S., Hsu, Y., Kim, J. S., Jackson, J. W., & Segal, J. B. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-09068-z · Cited by 2
The influence of anxiety and depressive disorders on the development of resistant arterial hypertension
Pchelenok, J. V., Fomicheva, A. V., Kanaeva, M., Rodionov, A. V., Tolokonin, A. O., & Volel, B. A. (2024) · Systemic Hypertension · doi:10.38109/2075-082x-2024-2-49-55 · Cited by 2
Hipertensión arterial: estilos de vida y estrategias de intervención
Mogollón, I. C. M., Silvera, E. E. G., Arias, A. P., & Barona, N. V. (2020) · Revista Científica de Enfermería · doi:10.14198/recien.2020.20.04 · Cited by 2
Treatment of Resistant Hypertension. Which Additional Antihypertensive Drugs?
Burnier, M., Bertschi, A. P., & Wuerzner, G. (2013) · Springer eBooks · doi:10.1007/978-88-470-5415-8_10 · Cited by 2
Are We on the Path to Solve the Enigma of Resistant Hypertension: Renal Sympathetic Denervation
Gerc, V., & Buksa, M. (2013) · Medical Archives · doi:10.5455/medarh.2013.67.454-459 · Cited by 2
ARTERIAL HYPERTENSION AND DIABETES MELLITUS: A QUEST FOR OPTIMAL TREATMENT — AN EXPERIENCE OF PERINDOPRIL A/AMLODIPINE USAGE
Потешкина, Н. Г. (2014) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2014-12-64-70 · Cited by 2
Prévalence de l’hypertension artérielle résistante chez des hypertendus non contrôlés adressés dans un centre de soins tertiaires
Henine, N., Kichou, B., Kichou, L., Benbouabdellah, M., Boubchir, M. A., Madiou, A., Hammouche, A., & Saheb, B. (2016) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2016.04.003 · Cited by 2
Hypertension résistante et maladie rénale chronique : épidémiologie et pronostic
Seidowsky, A., Massy, Z. A., Metzger, M., & Stengel, B. (2014) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2013.12.006 · Cited by 2
Evidence born from ASCOT trial – still important after 15 years
Rotar, О. P. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-3-46-53 · Cited by 2
The impact of renal denervation procedure on use of antihypertensive drugs in the real-life setting
Rea, F., Morabito, G., Savaré, L., Corrao, G., & Mancia, G. (2022) · Blood Pressure · doi:10.1080/08037051.2022.2126345 · Cited by 2
Evaluation of community-based care delivered by primary healthcare providers in management of hypertension in a rural area of West Bengal
Mukhopadhyay, P., De, M., Lahiri, S., Sarkar, M., & Haldar, A. (2023) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_2435_22 · Cited by 2
Renin angiotensin aldosterone system altered in resistant hypertension in Sub-Saharan African diabetes patients without evidence of primary hyperaldosteronism
EDINGA, B. E., Moor, V. J. A., Nansseu, J. R., Djoumessi, R. N., Mengnjo, M. K., Katte, J.-C. N., Noubiap, J. J., & Sobngwi, E. (2017) · JRSM Cardiovascular Disease · doi:10.1177/2048004017695006 · Cited by 2
Obesity, African American Race, Chronic Kidney Disease, and Resistant Hypertension
Judd, E. K., & Calhoun, D. A. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.06563 · Cited by 2
Need for fixed combination therapy in type-2 diabetes: Findings from the SMART study
Bruno, R. M., & Taddei, S. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318794261 · Cited by 2
Association of AGT (T704C) and NOS3 (G894T) Gene Polymorphisms with Treatment-Resistant Hypertension in the Uzbek Population
Masharipov, S., Абдуллаева, Г. Ж., Khamidullaeva, G., Zakirova, D. V., & Abdullaev, A. A. (2023) · International Journal of Biomedicine · doi:10.21103/article13(2)_oa1 · Cited by 1
Resistant Hypertension
Azizi, M., Lorthioir, A., & Amar, L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00047-5 · Cited by 2
Remnant Cholesterol is Associated with Blood Pressure Control in US Adults with Hypertension: NHANES 2007–2018 Analysis
Feng, S., Zou, S., Tang, M., Tian, R., & Xu, Y. (2025) · Vascular Health and Risk Management · doi:10.2147/vhrm.s553282 · Cited by 1
Incidence and prognosis of apparent-treatment resistant hypertension: a multi-state analysis using real world evidence
Teza, H., Anothaisintawee, T., Limpijankit, T., Tansawet, A., Boonmanunt, S. W., Pattanateepapon, A., McKay, G. J., Attia, J., & Thakkinstian, A. (2026) · Clinical Hypertension · doi:10.5646/ch.2026.32.e5 · Cited by 2
Device therapy of resistant hypertension
Simonyi, G., Bedros, J. R., & Medvegy, M. (2013) · Orvosi Hetilap · doi:10.1556/oh.2013.29543 · Cited by 1
Resistant Hypertension in Chronic Kidney Disease
Georgianos, P. I., & Sarafidis, P. A. (2016) · Springer eBooks · doi:10.1007/978-1-4939-6436-9_5 · Cited by 1
Definitions of Resistant Hypertension and Epidemiology of Resistant Hypertension
Ferro, C. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-56827-0_1 · Cited by 1
Resistant Hypertension and Cardiorenovascular Risk
Prkačin, I., Vrdoljak, P., Cavrić, G., Važanić, D., Pervan, P., & Adam, V. N. (2017) · BANTAO Journal · doi:10.1515/bj-2017-0002 · Cited by 1
ANTI-HYPERTENSIVE EFFECT OF RENAL ARTERIES RADIOFREQUENCY DENERVATION IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION
Gapon, L. I., Викторовна, М. Е., Savelyeva, N. Y., Kopylova, L. N., & Aleksandrovich, E. L. (2017) · Journal of clinical practice · doi:10.17816/clinpract833-9 · Cited by 1
Resistant Hypertension
Bobrie, G., Amar, L., Faucon, A., Madjalian, A.-M., & Azizi, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42973-3.00043-3 · Cited by 1
Practical use of single pill combinations in the treatment of hypertension — an analysis focused on perindopril-based combinations
Prejbisz, A., Dobrowolski, P., Doroszko, A., Filipiak, K. J., Januszewicz, A., Olszanecka, A., Narkiewicz, K., Tykarski, A., & Wolf, J. (2023) · Arterial Hypertension · doi:10.5603/ah.96726 · Cited by 2
Systematic Review and Meta-Analysis of Second-Generation Sham-Controlled Randomized Trials of Renal Denervation Therapy for Patients with Hypertension
Dantas, C. R., Lôbo, A. D. O. M., de Almeida, A. M., de Moraes, F. C. A., Sano, V. K. T., & Kelly, F. A. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00675-9 · Cited by 1
Сравнительная эффективность эналаприла и периндоприла по влиянию на центральное артериальное давление и упруго-эластические свойства артерий у пациентов с мягкой и умеренной артериальной гипертензией
Sirenko, Y., Rekovets, О. L., Kushnir, S., & Torbas, O. O. (2016) · HYPERTENSION · doi:10.22141/2224-1485.2.46.2016.74514 · Cited by 1
Resistant Hypertension: Recognition and Treatment
Oliva, R., & Bakris, G. L. (2022) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-030-95734-6_25 · Cited by 1
Resistance to antihypertensive treatment
de Leeuw, P. W. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834b8b52 · Cited by 1
Faculty Opinions recommendation of Resistant hypertension: detection, evaluation, and management: A scientific statement from the american heart association.
Manolis, A. J. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734299250.793571584 · Cited by 1
Can we use mineralocorticoid receptor blockade in diabetic patients with resistant hypertension? Yes we can! But it may be a double-edged sword
Azizi, M., Monge, M., Lorthioir, A., Bobrie, G., & Amar, L. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e328364bcdf
Impact of renal sympathetic denervation on home blood pressure monitoring in well defined patients with resistant hypertension
Franzen, K. F., Reppel, M., Neuwirth, M. G., Köster, J., Graf, T., Bode, F., Weil, J., & Mortensen, K. (2015) · Clinical Trials and Regulatory Science in Cardiology · doi:10.1016/j.ctrsc.2015.09.005
Recommandations pour la prise en charge des patients ayant une forme sévère d’hypertension artérielle
Plouin, P., & Fiessinger, J. (2012) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)31721-2
Resistente Hypertonie
Luft, F. C. (2015) · Der Internist · doi:10.1007/s00108-014-3568-9
QT Interval After Bariatric Surgery
Al‐Salameh, A., & Fysekidis, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804011-9.00057-1
Baroreceptor Activation for Hypertension and Heart Failure
Schneider, M. D., Yoruk, A., & Gassler, J. P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-805353-9.00107-8
¿Es útil el inicio de tratamiento con combinaciones antihipertensivas?
Gorostidi, M., & Prieto-Díaz, M. Á. (2017) · Hipertensión y Riesgo Vascular · doi:10.1016/s1889-1837(18)30059-x · Cited by 1
Comparison Therapies in the Treatment of Hypertension. The ASCOT and ACCOMPLISH Trial
Magkas, N., Kapota, A. I., & Tsioufis, C. P. (2018) · Springer eBooks · doi:10.1007/978-3-319-92946-0_10
Features of a circadian rhythm of arterial pressure in patients with resistant arterial hypertension and pseudo-resistant arterial hypertension
Sheremet, M. (2018) · Bukovinian Medical Herald · doi:10.24061/2413-0737.xxii.3.87.2018.74
Renal Denervation Therapy and Baroreceptor Activation Therapy: Emerging Tools for Treating Resistant Hypertension
Hart, P. D., Gosain, P., & Bakris, G. L. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2010-5_11
Arterial hypertension: modern advances in metabolomics
Zyryanov, S. K., Butranova, O. I., & Grishin, M. A. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-14-10-22
Resistant hypertension
Calhoun, D. A. (2013) · Hypertension · doi:10.2217/ebo.12.349
Current World Literature
(2012) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283558773
NEUROPSYCHOLOGICAL PROFILE IN PATIENTS WITH HYPERTENSIVE ENCEPHALOPATHY IN THE BACKGROUND OF RESISTANT ARTERIAL HYPERTENSION
SHARIPOVA, K. Y., Abdulloev, F. N., Гуломович, С. Р., RAKHIMOV, D. D., & NEGMATOV, G. M. (2022) · Avicenna Bulletin · doi:10.25005/2074-0581-2022-24-4-442-451
Hipertensión arterial resistente
Martínez, W. A. R., Mejía, A. F., & Cometa, L. A. V. (2023) · Interdisciplinary Journal of Epidemiology and Public Health · doi:10.18041/2665-427x/ijeph.2.9855
Greater use of antihypertensive medications explains lower blood pressures and better control in statin-treated than statin-eligible untreated adults
Egan, B. M., Li, J., Sutherland, S. E., & Rakotz, M. (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003656
Therapeutic intervention exploring hypertensive patients who respond to health coaching behavior modification therapy
Narita, K. (2024) · Hypertension Research · doi:10.1038/s41440-024-01601-1
Renal Denervation
Bertog, S. C., Vaškelytė, L., Drexel, T., Hofmann, I., Id, D., Gafoor, S. A., Reinartz, M., & Sievert, H. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-26219-4.00022-0
Management Strategies for Treatment-Resistant Hypertension: Current Status and Future Outlook
Thakare, S. B., Anandh, U., & Dasgupta, I. (2026) · Indian Journal of Nephrology · doi:10.25259/ijn_658_2025
The Association Between APOE Genotype, Race, and Dementia
Lakomski, N., Giorgio, K., Stephen, J. J., Mansolf, M. A., Soumaré, A., Gross, A. L., Aiello, A. E., Singh‐Manoux, A., Ikram, M. A., Helmer, C., et al. (2026) · Neurology Genetics · doi:10.1212/nxg.0000000000200417

Authors: Gupta, A. K., Nasothimiou, E. G., Chang, C. L., Sever, P. S., Dahlöf, B., & Poulter, N. R.
Affiliations: Imperial College London (GB)
Corresponding author: Gupta, Ajay K.
ORCID: Gupta, Ajay K.
Poulter, Neil R.
Venue: Journal of Hypertension
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2011-10
Volume: 29
Issue: 10
Pages: 2004-2013
ISSN: 0263-6352 (ISSN-L)
DOI: 10.1097/hjh.0b013e32834a8a42
OpenAlex: W2082072583
Cited by: 165
References: 26
Citations by year: 2026: 4 · 2025: 1 · 2024: 8 · 2023: 11 · 2022: 5 · 2021: 9 · 2020: 4 · 2019: 10 · 2018: 10 · 2017: 15 · 2016: 13 · 2015: 14 · 2014: 26 · 2013: 21 · 2012: 13
FWCI: 13.42
Type: journal article
Language: en
Open access: closed
Locations: Journal of Hypertension (publishedVersion)
PubMed (publishedVersion)
Funders: Pfizer
National Institute for Health and Care Research (NF-SI-0508-10116)
British Heart Foundation
Servier
National Institutes of Health
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
Keywords: resistant hypertension, baseline predictors, risk score, systolic blood pressure, antihypertensive therapy, amlodipine, perindopril, atenolol, thiazide diuretics, atorvastatin, aspirin, diabetes mellitus, left ventricular hypertrophy, alcohol consumption, body mass index, hypertension incidence, ASCOT trial
MeSH terms: Aged, Algorithms, Antihypertensive Agents, Atenolol, Bendroflumethiazide, Diuretics, Drug Resistance, Female, United Kingdom, Humans, Hypertension, Ireland, Male, Middle Aged, Risk Factors, Scandinavian and Nordic Countries, Amlodipine, Perindopril

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks